Ciprofloxacin (DB00537): A Comprehensive Monograph on its Pharmacology, Clinical Utility, Safety, and the Challenge of Antimicrobial Resistance

Executive Summary

Ciprofloxacin is a potent, broad-spectrum, second-generation fluoroquinolone antibiotic that has been a cornerstone of antimicrobial therapy for several decades. Identified by DrugBank ID DB00537 and CAS Number 85721-33-1, this small molecule agent exerts its bactericidal effect through the dual inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication. Its pharmacokinetic profile, characterized by excellent oral bioavailability and extensive tissue penetration, has made it a versatile option for treating a wide array of serious infections, particularly those caused by Gram-negative pathogens such as Pseudomonas aeruginosa. It is available in numerous formulations, including oral, intravenous, ophthalmic, and otic preparations, allowing for flexible treatment paradigms.

Despite its efficacy, the clinical utility of ciprofloxacin is increasingly challenged by two major factors: a significant safety profile and escalating bacterial resistance. Post-marketing surveillance has revealed the potential for serious, disabling, and potentially irreversible adverse reactions, prompting the U.S. Food and Drug Administration (FDA) to issue its most stringent "Black Box Warning." These warnings highlight risks of tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. Consequently, regulatory bodies, particularly in Europe, have placed significant restrictions on its use, advising against it for uncomplicated or self-limiting infections where safer alternatives exist.

Furthermore, the widespread and prolonged use of ciprofloxacin has driven the evolution of sophisticated bacterial resistance mechanisms. These include target-site mutations within the Quinolone-Resistance-Determining Region (QRDR), overexpression of efflux pumps that expel the drug, and the horizontal transfer of plasmid-mediated resistance genes. The emergence of ciprofloxacin-resistant strains in critical pathogens, such as Neisseria meningitidis, has forced changes in established public health protocols for disease prophylaxis.

This monograph provides a comprehensive analysis of ciprofloxacin, synthesizing data on its physicochemical properties, pharmacology, clinical indications, and safety. It details dosing guidelines for various populations, including pediatrics, geriatrics, and patients with renal impairment, and outlines significant drug and food interactions. Critically, it examines the molecular basis and epidemiological trends of bacterial resistance. The evidence presented underscores that ciprofloxacin, while still an indispensable tool for specific, severe infections, must be prescribed with caution and judiciousness. Its story serves as a powerful case study on the life cycle of an antibiotic and reinforces the urgent need for robust antimicrobial stewardship to preserve the efficacy of this important therapeutic class.

Section 1: Introduction and Drug Profile

1.1 Overview of Ciprofloxacin as a Second-Generation Fluoroquinolone

Ciprofloxacin is a synthetic, small-molecule antibiotic belonging to the fluoroquinolone class, a group of broad-spectrum antimicrobial agents.[1] As a second-generation fluoroquinolone, it represents a significant advancement over earlier quinolones like nalidixic acid. Its chemical structure is characterized by a quinolone core with two key modifications that enhance its therapeutic properties: the addition of a fluorine atom at position C-6 and a piperazine ring at position C-7.[3] These substitutions are responsible for its expanded spectrum of activity, particularly its potent efficacy against Gram-negative bacteria, including

Pseudomonas species, and its improved pharmacokinetic profile.[4]

Pharmacologically, ciprofloxacin is classified as an Anti-Bacterial Agent, a Topoisomerase II Inhibitor, and a Cytochrome P-450 (CYP) 1A2 Inhibitor.[3] Its primary mechanism of action is the inhibition of bacterial DNA synthesis, making it a powerful bactericidal agent against a wide variety of pathogens.

1.2 Historical Context and Initial FDA Approval

Ciprofloxacin was developed and patented by Bayer A.G. in 1983.[5] Following extensive clinical investigation, the first product containing ciprofloxacin received approval from the U.S. Food and Drug Administration (FDA) on October 22, 1987.[1] Its introduction into clinical practice marked a significant milestone in the treatment of bacterial infections, offering a highly effective oral option for many conditions that previously required intravenous therapy.

The long history of ciprofloxacin's use, spanning over three decades, has generated a vast body of evidence regarding its efficacy and applications. However, this extended period of widespread clinical use has also been instrumental in revealing the full scope of its safety profile and has created significant selective pressure, leading to the global emergence of bacterial resistance. The evolution of its clinical role—from a first-line workhorse to a more reserved agent—is a direct consequence of this long-term experience and serves as a critical lesson in the life cycle of an antibiotic.

1.3 Key Identification and Chemical Data

For precise identification and research purposes, ciprofloxacin is defined by the following key data:

• Generic Name: Ciprofloxacin [1]
• DrugBank ID: DB00537 [1]
• CAS Number: 85721-33-1 [6]
• Type/Modality: Small Molecule [1]
• Chemical Formula: C17​H18​FN3​O3​ [1]
• Average Molecular Weight: 331.34 g/mol.[6] Other reported values include 331.3415 g/mol and 331.35 g/mol.[1]
• Monoisotopic Weight: 331.133219662 Da [1]

Section 2: Physicochemical and Pharmaceutical Properties

2.1 Chemical Structure and Synonyms

The chemical identity of ciprofloxacin is defined by its specific structure and nomenclature.

• IUPAC Name: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid.[1]
• Structural Description: Ciprofloxacin is a quinolone derivative characterized by several key functional groups attached to its core structure. It is specifically a quinolin-4(1H)-one bearing a cyclopropyl group at position 1, a carboxylic acid group at position 3, a fluoro group at position 6, and a piperazin-1-yl substituent at position 7.[3] This unique combination of substituents dictates its pharmacological activity and spectrum.
• Synonyms and Brand Names: The drug is marketed and referenced under a variety of names globally, which is important for clinicians and researchers to recognize.
• Chemical Synonyms and Codes: BAY Q 3939, BAY-q 3939, and Bay 09867 are common research and development codes associated with the compound.[1]
• Brand Names: In the United States, common brand names include Cipro®, Cipro® XR (extended-release), and Proquin® XR.[9] In the United Kingdom and other regions, it is known as Ciproxin®, Ciloxan® (for ophthalmic/otic use), and Cetraxal®.[2] The European Medicines Agency (EMA) also recognizes associated names such as Ciprobay® and Ciprofloxacin BAYER®.[13]
• Combination Products: Ciprofloxacin is frequently formulated with corticosteroids for topical use, such as Ciprodex® (with dexamethasone) and Cipro® HC (with hydrocortisone), or with other agents like fluocinolone in Cetraxal® Plus.[1]

2.2 Physical Properties

The physical characteristics of ciprofloxacin influence its formulation, handling, and pharmacokinetic behavior.

Table 2.1: Physicochemical Properties of Ciprofloxacin

Property	Value	Source(s)
CAS Number	85721-33-1	6
Molecular Formula	C17​H18​FN3​O3​	1
Average Molecular Weight	331.34 g/mol - 331.35 g/mol	6
Appearance	White to almost-white powder or crystal	15
Melting Point	225–265 °C (with decomposition)	7
Solubility (at 25 °C)
Water	Insoluble	6
0.1N HCl	25 mg/mL	6
DMSO	<1 mg/mL	6
Ethanol	<1 mg/mL	6
Density	Approx. 1.5 g/cm³	7
Purity (Chemical Grade)	≥98%	6

The insolubility of ciprofloxacin in water at physiological pH necessitates formulation strategies such as the use of its hydrochloride salt or the creation of suspensions for oral administration.

2.3 Available Formulations

Ciprofloxacin's clinical versatility is reflected in the wide range of pharmaceutical formulations available, allowing for systemic and localized treatment.[1]

• Oral Formulations:
• Immediate-Release Tablets: Available in strengths of 100 mg, 250 mg, 500 mg, and 750 mg.[17]
• Extended-Release Tablets: Formulated to allow for once-daily dosing, available as 500 mg and 1000 mg tablets (e.g., Cipro® XR, Proquin® XR).[9]
• Oral Suspension: Provided as granules for reconstitution into a liquid, typically in concentrations of 5% (250 mg/5 mL) or 10% (500 mg/5 mL).[17] The oral suspension contains microcapsules and should not be chewed.[11] It is not recommended for administration through feeding tubes due to potential adherence to the tube material.[5]
• Intravenous (IV) Formulation: Supplied as a sterile solution for infusion, with common concentrations like 200 mg/100 mL and 400 mg/200 mL (2 mg/mL).[12] This allows for treatment of severe or life-threatening infections and for patients unable to take oral medication.
• Topical Formulations:
• Ophthalmic (Eye): Available as sterile eye drops (e.g., 0.3% w/v solution) for treating bacterial conjunctivitis and corneal ulcers.[5]
• Otic (Ear): Formulated as ear drops for treating otitis externa and otitis media, available as a single agent or in combination with corticosteroids like dexamethasone or hydrocortisone.[1]
• Intratympanic: A specialized formulation designed for direct administration into the middle ear has also been developed.[1]
• Investigational Formulation:
• Inhalation: A dry powder for inhalation has been granted orphan drug designation for the treatment of non-cystic fibrosis bronchiectasis (NCFB).[9] A Phase 1 clinical trial has evaluated the safety and pharmacokinetics of an inhaled ciprofloxacin powder in patients with Chronic Obstructive Pulmonary Disease (COPD).[22]

The diversity of these formulations facilitates tailored therapeutic approaches, including intravenous-to-oral switch therapy, which is a key component of antimicrobial stewardship in hospitalized patients. However, the variety of strengths and release mechanisms necessitates careful attention from prescribers and pharmacists to prevent dosing errors.

Section 3: Clinical Pharmacology

The clinical utility of ciprofloxacin is dictated by its pharmacodynamic and pharmacokinetic properties, which together determine its efficacy against bacterial pathogens and its potential for adverse effects.

3.1 Pharmacodynamics: Mechanism of Action

3.1.1 Dual Inhibition of DNA Gyrase and Topoisomerase IV

Ciprofloxacin's bactericidal activity stems from its potent inhibition of two essential bacterial enzymes belonging to the type II topoisomerase family: DNA gyrase (also known as topoisomerase II) and topoisomerase IV.[3] These enzymes play a critical role in managing the topology of bacterial DNA, a process vital for DNA replication, transcription, repair, and chromosome segregation.[23]

The enzymes function by creating a transient, double-stranded break in one segment of DNA (the "gate" or G-segment), allowing a second segment (the "transported" or T-segment) to pass through the break. The enzyme then reseals the G-segment.[23] Ciprofloxacin interferes with the breakage-reunion step of this reaction. It binds to and stabilizes the enzyme-DNA complex, known as the "cleavage complex," after the DNA has been cleaved but before the strands are religated.[3] This action effectively converts these essential enzymes into cellular toxins that generate permanent, lethal double-strand breaks in the bacterial chromosome, thereby halting DNA replication and triggering pathways that lead to rapid cell death.[3]

Ciprofloxacin primarily targets the A-subunits of these enzymes, which are encoded by the gyrA and parC genes.[1] The relative importance of each target varies between bacterial types. In most Gram-negative bacteria, DNA gyrase is the primary and more susceptible target, whereas in many Gram-positive bacteria, topoisomerase IV is the preferred target.[24]

3.1.2 Bactericidal Activity and Cellular Effects

The mechanism of action results in a potent bactericidal effect.[3] A significant advantage of ciprofloxacin over some other antibiotic classes, such as beta-lactams, is its ability to kill bacteria during both the logarithmic (rapid growth) and stationary phases of growth for key pathogens like

Escherichia coli and Pseudomonas aeruginosa.[3] This may contribute to its efficacy in infections where bacterial growth is slow or intermittent.

The drug exhibits a high degree of selective toxicity, binding to bacterial DNA gyrase with an affinity approximately 100 times greater than to its mammalian counterpart.[3] This selectivity is the foundation of its therapeutic index. However, this selectivity is not absolute. At high concentrations, ciprofloxacin can be cytotoxic to cultured mammalian cells by depleting mitochondrial DNA (mtDNA), suggesting a possible off-target interaction with a mitochondrial topoisomerase II-like enzyme.[3] This interaction may provide a molecular basis for some of the drug's characteristic toxicities, such as myopathy and neuropathy.

3.1.3 Mechanism of QT Interval Prolongation

A clinically important pharmacodynamic adverse effect of the fluoroquinolone class, including ciprofloxacin, is the prolongation of the QT interval on the electrocardiogram (ECG).[26] This effect arises from the blockade of voltage-gated potassium channels in cardiac myocytes. Specifically, fluoroquinolones inhibit the rapid component of the delayed rectifier potassium current, known as

IKr​, which is encoded by the human ether-a-go-go-related gene (HERG).[3] By blocking this current, the drugs delay the repolarization phase of the cardiac action potential. This manifests as a prolonged QT interval on the surface ECG and increases the risk for developing life-threatening polymorphic ventricular tachycardia, most notably Torsades de Pointes.

3.2 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

3.2.1 Bioavailability and Absorption

Ciprofloxacin is rapidly and effectively absorbed from the gastrointestinal tract following oral administration.[5] The absolute oral bioavailability is high, estimated to be approximately 70-80% by the FDA, with other studies reporting a range of 60-85%.[3] The drug does not undergo substantial first-pass metabolism, contributing to its high bioavailability.[29]

After an oral dose, peak serum concentrations (Cmax​) are typically reached within 1 to 2 hours (Tmax​).[5] The administration of immediate-release tablets with food can delay absorption, pushing the

Tmax​ to approximately 2 hours, but it does not significantly alter the overall drug exposure as measured by the area under the concentration-time curve (AUC).[29] In contrast, the bioavailability of the Proquin® XR extended-release formulation is significantly reduced when taken in a fasted state; therefore, it should be administered with a main meal to ensure adequate absorption.[3]

3.2.2 Volume of Distribution and Tissue Penetration

A key pharmacokinetic feature of ciprofloxacin is its wide distribution throughout the body. It has a large apparent volume of distribution (Vd​) of 2 to 3 L/kg, which indicates extensive penetration from the bloodstream into tissues.[3] This property is crucial for its efficacy in treating infections in deep-seated or poorly perfused tissues.

Tissue concentrations of ciprofloxacin often exceed corresponding serum concentrations. High levels are achieved in various bodily fluids and tissues, including saliva, nasal and bronchial secretions, sinus mucosa, sputum, peritoneal fluid, bile, and prostatic secretions, as well as in lung, skin, fat, muscle, cartilage, and bone tissue.[4] The drug's plasma protein binding is low, in the range of 30-39%.[4] This means a large fraction of the drug in circulation is unbound and pharmacologically active, allowing it to readily diffuse from the capillaries into the interstitial fluid where most bacterial infections reside.[30]

3.2.3 Metabolism via CYP1A2 and Key Metabolites

Ciprofloxacin is metabolized in the liver, primarily by the cytochrome P450 enzyme CYP1A2.[3] Its role as a moderate inhibitor of this enzyme is the underlying cause of several clinically significant drug-drug interactions.

Four principal metabolites have been identified: oxociprofloxacin and sulociprofloxacin are the main metabolites, each accounting for 3-8% of an administered dose. Desethylene ciprofloxacin and formylciprofloxacin are considered minor metabolites.[3] Collectively, these four metabolites represent approximately 15% of an oral dose and exhibit weaker antimicrobial activity than the parent ciprofloxacin molecule.[3]

3.2.4 Elimination Pathways and Half-Life

The serum elimination half-life (t1/2​) of ciprofloxacin in individuals with normal renal function is approximately 4 hours, with a reported range of 3 to 7 hours.[3]

Elimination occurs through both renal and non-renal pathways, with renal excretion being the predominant route. Approximately 40-50% of an oral dose is excreted unchanged in the urine.[3] The renal clearance of ciprofloxacin (approximately 300 mL/minute) is greater than the normal glomerular filtration rate (GFR) of 120 mL/minute, which indicates that active tubular secretion plays a significant role in its renal elimination, in addition to glomerular filtration.[5]

Non-renal elimination pathways include metabolism and excretion into the feces. Studies using radiolabeled ciprofloxacin have shown that up to 62% of a dose can be recovered in the feces over several days, representing a combination of unabsorbed drug, biliary excretion of the parent drug and its metabolites, and possibly direct intestinal secretion.[3]

Section 4: Antimicrobial Spectrum of Activity

The clinical use of ciprofloxacin is defined by its spectrum of activity, which encompasses a wide range of bacterial pathogens but also has notable gaps.

4.1 Gram-Negative and Gram-Positive Coverage

Ciprofloxacin is a broad-spectrum antibiotic, a characteristic that made it a highly valuable agent upon its introduction.[4] Its chemical structure, particularly the fluorine atom at C-6 and the piperazine moiety at C-7, confers potent activity against many Gram-negative bacteria and moderate activity against some Gram-positive bacteria.[4]

• Gram-Negative Activity: Ciprofloxacin exhibits excellent in vitro activity against the majority of Gram-negative pathogens. This includes most species of the family Enterobacteriaceae, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Salmonella typhi, and Shigella species.[1] It is also highly active against other clinically important Gram-negative organisms, including Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Neisseria meningitidis.[1]
• Gram-Positive Activity: Its activity against Gram-positive bacteria is more limited. It is active against methicillin-susceptible Staphylococcus aureus (MSSA) and some strains of Enterococcus faecalis.[4] However, its potency against these organisms is generally lower than its activity against Gram-negatives, and resistance is common.[32]

4.2 Activity Against Key Pathogens

Ciprofloxacin's role in modern medicine is heavily reliant on its efficacy against specific, often difficult-to-treat, pathogens.

• Pseudomonas aeruginosa: One of the most important features of ciprofloxacin's spectrum is its reliable activity against P. aeruginosa. It is one of the few orally available antibiotics effective for infections caused by this opportunistic pathogen, which is a common cause of hospital-acquired pneumonia, infections in burn patients, and chronic respiratory infections in individuals with cystic fibrosis.[4] The piperazine group in its structure is specifically credited with enhancing this anti-pseudomonal activity.[4]
• Bacillus anthracis: Ciprofloxacin is a first-line agent recommended by public health authorities for the treatment and post-exposure prophylaxis of anthrax, a critical role in biodefense preparedness.[1]
• Yersinia pestis: Similarly, it is indicated for the treatment and prophylaxis of plague, another potential bioterrorism agent.[1]
• Atypical Pathogens: The drug is also effective against "atypical" respiratory pathogens, most notably Legionella pneumophila, the causative agent of Legionnaires' disease.[4]

4.3 Limitations in Spectrum

Despite its broad spectrum, ciprofloxacin has significant limitations that restrict its empirical use in certain clinical scenarios.

• Streptococcus pneumoniae: Ciprofloxacin possesses only modest and often unreliable activity against S. pneumoniae, one of the most common pathogens responsible for community-acquired pneumonia (CAP).[32] Because of this gap in coverage, treatment guidelines generally do not recommend ciprofloxacin as a first-line monotherapy for CAP. Instead, "respiratory quinolones" such as levofloxacin or moxifloxacin, which have been structurally modified to have enhanced activity against S. pneumoniae, are preferred for this indication.[32]
• Anaerobic Bacteria: Ciprofloxacin has poor activity against the majority of anaerobic bacteria. This is a critical consideration for treating mixed infections where anaerobes are likely to be involved, such as complicated intra-abdominal infections or certain types of skin and soft tissue infections (e.g., diabetic foot ulcers). In these cases, ciprofloxacin must be administered in combination with an agent that provides robust anaerobic coverage, such as metronidazole.[1]
• Emerging Resistance: The initial potent activity against organisms like N. gonorrhoeae has been severely compromised by the widespread development of resistance, rendering ciprofloxacin obsolete for the treatment of gonorrhea in many parts of the world.[32] This trend highlights the dynamic nature of an antibiotic's spectrum of activity over time.

The clinical implication of this specific spectrum is profound. Ciprofloxacin's strength against Gram-negative rods established its role in treating complicated UTIs, hospital-acquired infections, and osteomyelitis. However, this very utility led to its extensive use, which in turn created the selective pressure that has driven the emergence of resistant strains, particularly in P. aeruginosa. This feedback loop, where clinical success contributes to future clinical failure, is a central theme in the history of antibiotics and underscores the importance of antimicrobial stewardship.

Section 5: Clinical Efficacy and Regulatory Status

The approved uses of ciprofloxacin are extensive but are increasingly being curtailed by regulatory agencies in response to its evolving safety profile and the availability of safer alternatives for less severe infections. There is a notable divergence in the regulatory approach between the United States and Europe.

5.1 FDA-Approved Indications (United States)

The U.S. Food and Drug Administration (FDA) has approved ciprofloxacin for the treatment of a wide variety of infections, provided they are caused by susceptible strains of designated microorganisms.[3]

• Key Systemic Indications:
• Urinary Tract Infections (UTIs): Including acute uncomplicated cystitis, complicated UTIs, and pyelonephritis.[3]
• Lower Respiratory Tract Infections (LRTIs): Including acute bacterial exacerbations of chronic bronchitis and nosocomial pneumonia.[1]
• Skin and Skin Structure Infections.[1]
• Bone and Joint Infections.[1]
• Complicated Intra-abdominal Infections: Used in combination with metronidazole to ensure anaerobic coverage.[1]
• Prostatitis: For both acute and chronic bacterial prostatitis.[1]
• Infectious Diarrhea and Typhoid Fever.[5]
• Sexually Transmitted Infections: Including uncomplicated gonococcal infections and chancroid, though resistance has made its use for gonorrhea largely obsolete.[5]
• Bioterrorism and Special Pathogens: Ciprofloxacin holds critical indications for the treatment and post-exposure prophylaxis of inhalational anthrax and for the treatment and prophylaxis of plague (pneumonic and septicemic) caused by Yersinia pestis.[1]
• Important Usage Limitation: A pivotal shift in FDA guidance is the issuance of a "Limitations of Use" statement. For acute sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs, the FDA advises that fluoroquinolones like ciprofloxacin be reserved for patients who have no alternative treatment options. This is a direct acknowledgment that the risks of serious side effects generally outweigh the benefits for these less severe conditions.[9]

5.2 EMA-Approved Indications and Prescribing Restrictions (Europe)

The European Medicines Agency (EMA) and national regulatory bodies like the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have adopted a more restrictive stance on the use of fluoroquinolones. While they approve ciprofloxacin for many of the same serious infections as the FDA (e.g., complicated UTIs, LRTIs, bone and joint infections, anthrax), they have imposed stricter limitations to mitigate the risk of disabling and potentially irreversible side effects.[39]

• Explicit Restrictions on Use: European guidance explicitly states that fluoroquinolones should not be prescribed for:
• Treating non-severe or self-limiting infections, such as pharyngitis (throat infections).[40]
• Treating non-bacterial conditions, such as non-bacterial (chronic) prostatitis.[40]
• Prophylaxis of traveler's diarrhea or recurrent lower UTIs.[40]
• Treating mild or moderate bacterial infections (including acute bronchitis and uncomplicated cystitis) unless other commonly recommended antibiotics are considered inappropriate or have failed.[40]

This regulatory divergence reflects a different weighing of the risk-benefit equation. The FDA's approach is a strong advisory, leaving final discretion to the clinician, whereas the EMA's guidance is a more direct directive to restrict use. This difference has significant implications for clinical practice guidelines, physician liability, and public health policy on either side of the Atlantic. The need for a formal SPC harmonization procedure within the EU, initiated in 2007, underscores the recognized importance of establishing a unified, restrictive policy across member states.[13]

Table 5.1: Comparative Overview of FDA and EMA Approved Indications for Ciprofloxacin

Indication	FDA Status / Guidance	EMA Status / Guidance
Complicated UTI / Pyelonephritis	Approved 11	Approved 39
Uncomplicated UTI (Cystitis)	Approved, but reserve for patients with no other options due to safety risks 9	Approved, but should not be used unless other antibiotics are inappropriate 40
Acute Bacterial Exacerbation of Chronic Bronchitis	Approved, but reserve for patients with no other options due to safety risks 9	Should not be used unless other antibiotics are inappropriate 41
Acute Sinusitis	Approved, but reserve for patients with no other options due to safety risks 9	Approved, but generally restricted for severe cases 39; non-severe infections are a contraindication 40
Bone & Joint Infections	Approved 1	Approved 39
Inhalational Anthrax / Plague	Approved; critical indication 1	Approved; critical indication 39
Prophylaxis of Traveler's Diarrhea	Not a primary indication; off-label use discouraged	Explicitly not recommended for this use 40

5.3 Overview of Clinical Trial Data

The long history of ciprofloxacin is supported by an extensive portfolio of clinical trials that have investigated its use across numerous indications and patient populations.

• Completed Trials: DrugBank documents a large number of completed trials. These include:
• Phase 3: Studies evaluating ciprofloxacin for various bacterial diseases, such as in the treatment of infections in burned patients and for infection prophylaxis during transrectal prostate biopsies.[43]
• Phase 2: Trials assessing its utility in critically ill patients suffering from conditions like hospital-acquired infections, pneumonia, and Systemic Inflammatory Response Syndrome (SIRS).[44]
• Phase 1: Studies exploring novel formulations, such as a single-dose inhalation powder for patients with Chronic Obstructive Pulmonary Disease (COPD).[22]
• Other: Trials have also been completed for indications like upper respiratory tract infections.[45]
• Ongoing Trials: The drug continues to be studied. For example, a Phase 4 post-marketing trial is currently recruiting participants to evaluate its role in antibiotic prophylaxis for cat bite wounds.[46] This demonstrates that even for a well-established drug, new clinical questions and applications continue to be explored.

Section 6: Safety Profile and Tolerability

The safety profile of ciprofloxacin is complex and has evolved significantly over time, culminating in some of the most stringent warnings issued by regulatory authorities for an antibiotic. The primary concern is the risk of serious, disabling, and potentially irreversible adverse reactions.

6.1 FDA Black Box Warning: A Detailed Analysis

In recognition of the severity of potential adverse effects, the U.S. FDA has mandated a "Boxed Warning"—its highest level of warning—for the entire fluoroquinolone class, including ciprofloxacin. The warning emphasizes that these drugs are associated with a constellation of serious adverse reactions that can occur together and may be permanent.[26] The core components of this warning are:

6.1.1 Tendinitis and Tendon Rupture

This is one of the most well-known and concerning risks associated with ciprofloxacin. The risk of developing tendinitis (inflammation of a tendon) or a complete tendon rupture is increased in patients of all ages.[47] The Achilles tendon is the most frequently affected site, but ruptures can also occur in the shoulder, hand, or other tendons.[47] The onset can be rapid, occurring within hours of the first dose, or delayed, manifesting up to several months after treatment has been completed.[41] The risk is significantly elevated in certain populations:

• Patients older than 60 years of age.[48]
• Patients receiving concomitant corticosteroid therapy.[37]
• Recipients of a kidney, heart, or lung transplant.[48]

6.1.2 Peripheral Neuropathy

Ciprofloxacin can cause a sensory or sensorimotor axonal neuropathy, which involves damage to the peripheral nerves.[26] Symptoms include pain, burning, tingling, numbness, and/or weakness in the extremities.[48] The onset of neuropathy can be rapid, sometimes occurring within a few days of starting the drug. Critically, this nerve damage can be permanent, even after discontinuation of ciprofloxacin.[38]

6.1.3 Central Nervous System (CNS) Effects

A wide spectrum of CNS adverse effects has been reported, which can occur even after a single dose.[48] These effects range from relatively mild to severe and life-threatening. Reported events include:

• Neurological: Seizures, tremors, dizziness, and lightheadedness.[48]
• Psychiatric: Confusion, agitation, paranoia, hallucinations, anxiety, depression, panic attacks, insomnia, nightmares, and, in rare cases, suicidal thoughts or behaviors.[26]

6.1.4 Exacerbation of Myasthenia Gravis

Fluoroquinolones are known to exacerbate muscle weakness in patients with myasthenia gravis, a chronic autoimmune neuromuscular disorder.[26] This can lead to profound weakness, respiratory failure requiring mechanical ventilation, and even death. Consequently, ciprofloxacin should be avoided in patients with a known history of myasthenia gravis.[26]

This constellation of toxicities has fundamentally altered the risk-benefit assessment for ciprofloxacin. The recognition that these disabling events could occur together and be irreversible prompted the FDA in 2016 to significantly strengthen the warnings and advise against the use of fluoroquinolones for common infections where safer alternatives are available.[27] This regulatory evolution was influenced by years of post-marketing reports and advocacy from patient communities who described a multi-system toxicity syndrome, sometimes referred to as being "floxed".[38]

6.2 Common and Serious Adverse Reactions

Beyond the boxed warnings, ciprofloxacin is associated with a range of other adverse effects.

• Common Side Effects: The most frequently reported adverse reactions are gastrointestinal in nature and are typically mild to moderate. These include nausea, vomiting, diarrhea, and abdominal pain.[9] Transient elevations in liver enzymes (abnormal liver function tests) and skin rash are also common.[9]
• Serious Adverse Reactions:
• Cardiovascular: In addition to QT prolongation (discussed in Section 3.1.3), emerging evidence links fluoroquinolone use to an increased risk of aortic aneurysm and dissection.[37] The proposed mechanism involves the degradation of collagen, a key structural component of both tendons and the aortic wall, potentially unifying these two distinct adverse outcomes under a single pathogenic pathway.
• Dermatologic: Photosensitivity and phototoxicity are known risks, making patients more susceptible to severe sunburn. Patients should be advised to avoid excessive sun exposure and use high-SPF sunscreen.[11] Rare but severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported.[55]
• Metabolic: Disturbances in blood glucose, including both severe hypoglycemia (which can lead to coma and be fatal) and hyperglycemia, have been reported. The risk is highest in patients with diabetes, especially those taking oral hypoglycemic agents.[26]
• Gastrointestinal: As with most broad-spectrum antibiotics, ciprofloxacin disrupts the normal gut flora, which can lead to an overgrowth of Clostridioides difficile and subsequent C. difficile-associated diarrhea (CDAD), ranging from mild diarrhea to life-threatening colitis.[28]
• Renal: Crystalluria (the formation of drug crystals in the urine) can occur, particularly with high doses or in alkaline urine. Maintaining adequate hydration is essential to minimize this risk.[26] Cases of acute interstitial nephritis and renal failure have also been reported.[55]
• Hepatic: Severe hepatotoxicity, including cases of fulminant hepatitis and acute liver failure, has been reported, although rarely. The drug should be discontinued immediately if signs and symptoms of hepatitis develop (e.g., jaundice, dark urine, anorexia, abdominal tenderness).[28]

6.3 Contraindications and Hypersensitivity Reactions

• Contraindications:
• Ciprofloxacin is contraindicated in patients with a history of hypersensitivity to ciprofloxacin or any other member of the quinolone class.[28]
• Concomitant administration with the muscle relaxant tizanidine is contraindicated due to a significant drug interaction that can lead to severe hypotension and sedation.[10]
• Hypersensitivity: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions can occur, sometimes following the very first dose. Any sign of hypersensitivity, such as a skin rash, hives, or jaundice, warrants immediate discontinuation of the drug and medical evaluation.[26]

Section 7: Dosing and Administration

The appropriate dosing of ciprofloxacin is highly dependent on the specific indication, the severity of the infection, the formulation used, and key patient-specific factors such as age, weight, and renal function.

7.1 Adult Dosing by Indication and Formulation

The following table summarizes typical adult dosing regimens based on FDA and EMA guidelines. It is essential to consult official prescribing information for the most current recommendations.

Table 7.1: Ciprofloxacin Dosing Guidelines for Adult, Pediatric, and Special Populations

Patient Population/Condition	Indication	Formulation	Recommended Dose	Frequency	Usual Duration	Source(s)
Adults	Uncomplicated UTI (Cystitis)	Oral (IR)	250 mg	Every 12 hours	3 days	28
		Oral (ER)	500 mg	Once daily	3 days	11
	Complicated UTI / Pyelonephritis	Oral (IR)	500 mg	Every 12 hours	7-14 days	28
		Oral (ER)	1000 mg	Once daily	7-14 days	11
		IV	400 mg	Every 12 hours	7-14 days	5
	Lower Respiratory, Skin, Bone & Joint Infections	Oral (IR)	500–750 mg	Every 12 hours	7 days to 8 weeks	17
		IV	400 mg	Every 8-12 hours	Varies	5
	Inhalational Anthrax (Post-exposure)	Oral (IR)	500 mg	Every 12 hours	60 days	28
		IV	400 mg	Every 12 hours	60 days	36
Pediatrics (1-17 years)	Complicated UTI / Pyelonephritis	Oral	10–20 mg/kg (max 750 mg/dose)	Every 12 hours	10–21 days	28
		IV	6–10 mg/kg (max 400 mg/dose)	Every 8 hours	10–21 days	61
	Inhalational Anthrax (Post-exposure)	Oral	15 mg/kg (max 500 mg/dose)	Every 12 hours	60 days	28
	Plague	Oral	15 mg/kg (max 500 mg/dose)	Every 8-12 hours	14 days	28
Renal Impairment (Adults)	CrCl 30–50 mL/min	Oral/IV	250–500 mg	Every 12 hours	Varies	5
	CrCl 5–29 mL/min	Oral/IV	250–500 mg	Every 18 hours	Varies	5
	Hemodialysis / Peritoneal Dialysis	Oral/IV	250–500 mg	Every 24 hours (after dialysis)	Varies	5
Geriatrics	All	All	Use with caution; dose adjustment may be needed based on renal function. Increased risk of tendon rupture and other serious AEs.	-	-	40
Pregnancy	All	Systemic	Avoid unless benefit clearly outweighs risk (e.g., anthrax). FDA Category C.	-	-	64
Lactation	All	Systemic	Passes into breast milk. Use with caution, monitor infant. Some sources advise avoiding breastfeeding.	-	-	64

IR = Immediate-Release, ER = Extended-Release, CrCl = Creatinine Clearance, UTI = Urinary Tract Infection, AE = Adverse Event

7.2 Use in Special Populations

7.2.1 Pediatric Use: Approved Indications, Dosing, and Safety Concerns (Arthropathy)

The use of ciprofloxacin in children has historically been limited due to concerns about arthropathy (joint disease), which was observed in studies involving juvenile animals.[69] These animal studies showed irreversible cartilage damage. However, decades of clinical experience in pediatric patients have provided a more nuanced picture. While musculoskeletal adverse events, primarily reversible arthralgia (joint pain), are the most frequently reported issues (occurring in approximately 1-3% of treated children), permanent cartilage damage has not been conclusively demonstrated in humans.[69]

Given this risk-benefit profile, the FDA has restricted the approved indications for ciprofloxacin in the pediatric population (ages 1 to 17 years) to scenarios where the benefits are deemed to outweigh the potential risks. The only FDA-approved indications are:

1. Complicated Urinary Tract Infections and Pyelonephritis.[28]
2. Inhalational Anthrax (Post-exposure).[28]

For these indications, it is not considered a first-line agent.[32] Dosing in children is based on body weight, typically in the range of 10–20 mg/kg orally every 12 hours or 6–10 mg/kg intravenously every 8 hours, with specified maximum doses per dose that should not be exceeded.[28]

7.2.2 Geriatric Use: Heightened Risks and Considerations

Elderly patients (generally defined as >60 years old) are particularly vulnerable to the serious adverse effects of ciprofloxacin. They have a significantly increased risk of tendinitis and tendon rupture, especially if they are also taking corticosteroids.[40] This population is also more susceptible to CNS effects like confusion, delirium, and agitation, which can be mistakenly attributed to dementia or other age-related cognitive changes.[51] Furthermore, the risk of QT interval prolongation is higher in older adults, who have a greater prevalence of underlying heart disease and concomitant use of other QT-prolonging drugs.[63]

Pharmacokinetic changes also play a role, as age-related decline in renal function is common. This can lead to drug accumulation and an increased risk of toxicity if doses are not adjusted appropriately.[50] Peak serum concentrations and overall drug exposure (AUC) are known to be slightly higher in geriatric patients compared to younger adults.[3]

7.2.3 Renal Impairment: Dose Adjustment Guidelines

Since ciprofloxacin is primarily eliminated by the kidneys, dosage adjustments are mandatory for patients with impaired renal function to prevent drug accumulation and toxicity.[58] The standard approach is to modify the dose or extend the dosing interval based on the patient's creatinine clearance (CrCl). The FDA-recommended adjustments for adults are outlined in Table 7.1.[5]

An important pharmacodynamic consideration arises in how the dose is adjusted. Ciprofloxacin exhibits concentration-dependent killing, meaning that higher peak concentrations relative to the pathogen's MIC are associated with more rapid and effective bacterial eradication. A simulation study has suggested that for concentration-dependent antibiotics like ciprofloxacin, prolonging the administration interval (e.g., giving a full 500 mg dose every 24 hours) may be more effective at achieving bacterial eradication in patients with renal failure than reducing the dose size while maintaining the same interval (e.g., giving 250 mg every 12 hours).[74] This is because the interval extension strategy preserves the high peak concentration that drives bactericidal activity. This principle represents a more sophisticated approach to dosing in renal impairment that aligns with the drug's fundamental pharmacology.

7.2.4 Hepatic Impairment: Dosing Considerations

In patients with stable chronic liver cirrhosis, the pharmacokinetics of ciprofloxacin are not significantly altered, provided renal function is normal. Therefore, dose adjustments are generally not required based on hepatic impairment alone.[29] However, ciprofloxacin itself carries a risk of hepatotoxicity, and cases of severe and sometimes fatal hepatic failure have been reported.[28] If a patient develops signs or symptoms of hepatitis during treatment, the drug should be discontinued immediately. The pharmacokinetics in patients with acute hepatic insufficiency have not been fully characterized.[29]

7.2.5 Use in Pregnancy and Lactation

• Pregnancy: Systemic ciprofloxacin is generally not recommended for use during pregnancy (US FDA Pregnancy Category C; Australian TGA Category B3).[64] While human observational studies have not found a clear link to major malformations, the data are insufficient to rule out risk entirely.[66] Based on the arthropathy seen in juvenile animal studies, there remains a theoretical concern for adverse effects on fetal cartilage development.[65] Its use should be reserved for compelling indications where the potential benefit to the mother is judged to outweigh the potential risk to the fetus, such as in the treatment of inhalational anthrax.[5] Topical formulations (otic and ophthalmic) are considered acceptable as systemic absorption is minimal.[64]
• Lactation: Ciprofloxacin is known to pass into breast milk in small amounts.[64] While the risk to the infant is likely low, and some authorities consider it acceptable with close monitoring of the infant (for signs like diarrhea, rash, or thrush), other sources advise against breastfeeding during treatment and for 48 hours after the final dose.[67] To minimize infant exposure, breastfeeding can be avoided during the period of peak milk concentrations, which is approximately 3 to 4 hours after a maternal dose.[68]

Section 8: Significant Drug and Food Interactions

Ciprofloxacin is subject to numerous clinically significant interactions that can alter its efficacy or increase the risk of toxicity from either ciprofloxacin or concomitant medications. These interactions stem primarily from two distinct properties: its chemical structure, which allows for chelation, and its metabolic profile as an inhibitor of the CYP1A2 enzyme.

8.1 Pharmacokinetic Interactions

Chelation (Decreased Absorption)

The most common and impactful pharmacokinetic interaction involves the chelation of ciprofloxacin by polyvalent cations in the gastrointestinal tract. Ciprofloxacin binds to cations such as calcium, magnesium, aluminum, iron, and zinc, forming insoluble complexes that are poorly absorbed.[76] This can lead to a drastic reduction in bioavailability (by as much as 90%) and potential therapeutic failure.[29]

• Interacting Agents: This interaction is relevant for a wide range of common products, including:
• Antacids containing magnesium or aluminum (e.g., Maalox®, Mylanta®) or calcium carbonate (e.g., Tums®).[78]
• Dietary supplements containing iron, calcium, or zinc.[79]
• The antiretroviral drug didanosine (which contains a buffered formulation).[80]
• Phosphate binders like sevelamer and lanthanum carbonate.[78]
• The cytoprotective agent sucralfate.[78]
• Management: To prevent this interaction, ciprofloxacin should be administered at least 2 hours before or 4 to 6 hours after any of these products.[5] This timing separation is a critical patient counseling point.

CYP1A2 Inhibition

Ciprofloxacin is a moderate inhibitor of the hepatic enzyme CYP1A2. This inhibition slows the metabolism of other drugs that are substrates of this enzyme, leading to increased plasma concentrations and a heightened risk of their associated toxicities.[3]

• Theophylline: This is a classic and potentially life-threatening interaction. Ciprofloxacin can significantly increase theophylline levels, leading to toxicity that includes seizures, cardiac arrest, and respiratory failure. The combination should be avoided if possible. If co-administration is necessary, serum theophylline concentrations must be monitored closely and the theophylline dose adjusted accordingly.[76]
• Tizanidine: Concomitant use is contraindicated. Ciprofloxacin dramatically increases exposure to tizanidine, leading to a profound risk of severe hypotension and sedation.[10]
• Caffeine: Ciprofloxacin reduces the clearance of caffeine, prolonging its effects and potentially causing symptoms of caffeine toxicity such as nervousness, insomnia, palpitations, and tremors. Patients should be advised to limit their intake of coffee, tea, cola, and other caffeine-containing products.[76]
• Other CYP1A2 Substrates: Ciprofloxacin can also increase levels of duloxetine (Cymbalta®), clozapine, and others. The combination with duloxetine can increase its levels five-fold and should be avoided.[76]

8.2 Pharmacodynamic Interactions

These interactions occur when ciprofloxacin and another drug have additive or synergistic effects on a physiological system.

• QT Interval Prolongation: The intrinsic risk of QT prolongation with ciprofloxacin is additive when it is co-administered with other drugs that share this property. This increases the risk of Torsades de Pointes. Such combinations should be avoided. Interacting drugs include:
• Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmics.[63]
• Certain antipsychotics (e.g., ziprasidone, thioridazine), tricyclic antidepressants, and macrolide antibiotics.[10]
• Warfarin: Ciprofloxacin can enhance the anticoagulant effect of warfarin, increasing the international normalized ratio (INR) and the risk of serious bleeding. The mechanism is not fully understood but may involve inhibition of warfarin metabolism or disruption of vitamin K-producing gut flora. Close monitoring of INR is essential if these drugs must be used together.[26]
• Hypoglycemic Agents: Ciprofloxacin can potentiate the effects of oral diabetes medications, particularly sulfonylureas (e.g., glyburide, glipizide), leading to an increased risk of severe hypoglycemia. Patients, especially those with diabetes, should be counseled on this risk and instructed to monitor their blood glucose levels closely.[26]

8.3 Food and Food-Supplement Interactions

Table 8.1: Major Drug Interactions with Ciprofloxacin and Management Strategies

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Tizanidine	CYP1A2 Inhibition	Severe hypotension and sedation	Contraindicated. Avoid concomitant use.	10
Theophylline	CYP1A2 Inhibition	Increased theophylline levels, risk of severe toxicity (seizures, cardiac arrest)	Avoid combination if possible. If necessary, monitor theophylline levels closely and adjust dose.	76
Warfarin	Enhanced anticoagulant effect (mechanism multifactorial)	Increased risk of bleeding	Monitor INR/prothrombin time closely and adjust warfarin dose as needed.	26
QT-Prolonging Agents (e.g., Class IA/III antiarrhythmics, certain antipsychotics)	Additive pharmacodynamic effect on cardiac repolarization	Increased risk of QT prolongation and Torsades de Pointes	Avoid concomitant use, especially in patients with other risk factors.	28
Cation-Containing Products (Antacids, Iron/Calcium/Zinc supplements, Sevelamer, Sucralfate)	Chelation in GI tract	Markedly decreased ciprofloxacin absorption and potential therapeutic failure	Administer ciprofloxacin at least 2 hours before or 4-6 hours after the interacting product.	77
Sulfonylureas (e.g., Glyburide)	Potentiation of hypoglycemic effect	Increased risk of severe hypoglycemia	Monitor blood glucose closely.	26
Duloxetine	CYP1A2 Inhibition	Markedly increased duloxetine levels (up to 5-fold)	Avoid combination.	76

• Dairy Products and Calcium-Fortified Foods: Due to the chelation interaction, ciprofloxacin should not be taken alone with dairy products like milk or yogurt, or with juices that are fortified with calcium. These can significantly reduce its absorption. However, it is generally considered acceptable to take ciprofloxacin as part of a mixed meal that contains these food items. A time separation of at least 2 hours is recommended if consuming these products outside of a meal.[37]
• Enteral (Tube) Feedings: Continuous enteral nutrition can significantly decrease the absorption of oral ciprofloxacin tablets. To manage this, it is recommended to stop the feeding for 1 to 2 hours before the ciprofloxacin dose and for 2 to 6 hours after administration.[77] The oral suspension formulation should not be administered via feeding tubes at all.[5]

The breadth of these interactions, involving common over-the-counter medications, prescription drugs, and dietary staples, makes ciprofloxacin a high-risk medication that demands thorough medication reconciliation and proactive patient education to ensure both safety and efficacy.

Section 9: Mechanisms and Trends in Bacterial Resistance

The long-term clinical utility of ciprofloxacin is profoundly threatened by the global rise of antimicrobial resistance. The development of resistance is a complex and multifactorial process, driven by the strong selective pressure exerted by the widespread use of the drug. Understanding the molecular mechanisms and epidemiological trends of resistance is critical for guiding antimicrobial stewardship efforts and preserving the efficacy of the fluoroquinolone class.

9.1 Molecular Mechanisms of Resistance

Bacteria have evolved several distinct mechanisms to evade the bactericidal effects of ciprofloxacin. Often, high-level clinical resistance results from the accumulation of multiple mechanisms within a single organism.[84]

Table 9.1: Summary of Bacterial Resistance Mechanisms to Ciprofloxacin

Mechanism Category	Specific Mechanism	Key Genes/Proteins Involved	Consequence	Source(s)
Target-Site Modification	Mutations in the Quinolone-Resistance-Determining Region (QRDR)	gyrA, gyrB (DNA gyrase) parC, parE (Topoisomerase IV)	Weakened drug binding to the enzyme-DNA complex, preventing stabilization of the cleavage complex. This is the most common and clinically significant mechanism.	24
Reduced Intracellular Concentration	Decreased Influx (Permeability)	Downregulation of porin proteins (e.g., OmpF in E. coli)	Reduced entry of the drug into the bacterial cell, particularly in Gram-negative bacteria.	24
	Increased Efflux	Overexpression of chromosomal multidrug efflux pumps (e.g., AcrAB-TolC, Mex pumps)	Active transport of the drug out of the cell, lowering intracellular concentration. Often caused by mutations in repressor genes (marR, acrR, nfxB).	6
Plasmid-Mediated Quinolone Resistance (PMQR)	Target Protection	Qnr proteins (e.g., QnrA, QnrB, QnrS)	Proteins bind to and shield DNA gyrase/topoisomerase IV from ciprofloxacin.	24
	Drug Modification	Aminoglycoside acetyltransferase variant aac(6')-Ib-cr	Enzymatic acetylation of the piperazine ring on ciprofloxacin, reducing its activity.	25
	Plasmid-Encoded Efflux	Efflux pumps (e.g., OqxAB, QepA)	Additional efflux capacity acquired via mobile genetic elements.	25

9.1.1 Target-Site Mutations

The most prevalent and effective mechanism of resistance involves alterations in the drug's primary targets, DNA gyrase and topoisomerase IV.[25] These alterations are typically point mutations occurring within specific, highly conserved segments of the

gyrA, gyrB, parC, or parE genes. This critical area is known as the Quinolone-Resistance-Determining Region (QRDR).[24] Mutations in the QRDR change the amino acid sequence at the drug's binding site, weakening the affinity between ciprofloxacin and the enzyme-DNA complex. This prevents the drug from effectively trapping the cleavage complex, allowing DNA replication to proceed.[25] A single mutation typically confers low-to-moderate resistance, while high-level resistance, common in clinical isolates, usually results from the stepwise accumulation of mutations in both the primary and secondary target enzymes.[25]

9.1.2 Altered Permeability and Efflux Pump Overexpression

These mechanisms function by reducing the intracellular concentration of ciprofloxacin, preventing it from reaching its targets in sufficient quantities.[24]

• Decreased Influx: In Gram-negative bacteria, the outer membrane acts as a selective barrier. Ciprofloxacin enters the periplasmic space through protein channels called porins. Mutations that lead to the downregulation or loss of these porins (e.g., OmpF in E. coli) can reduce drug uptake and contribute to resistance.[24]
• Increased Efflux: Bacteria possess chromosomally-encoded efflux pumps, which are membrane transporters that actively expel a wide range of toxic substances, including antibiotics. Overexpression of these pumps (e.g., the AcrAB-TolC system in E. coli or the Mex family of pumps in P. aeruginosa) is a common resistance mechanism.[6] This overexpression is often the result of mutations in local regulatory genes that normally act as repressors (e.g., marR, nfxB). When these repressors are inactivated, the pumps are constitutively produced at high levels, efficiently removing ciprofloxacin from the cell.[24]

9.1.3 Plasmid-Mediated Quinolone Resistance (PMQR)

A particularly concerning development is the emergence of resistance genes located on plasmids—mobile genetic elements that can be transferred between bacteria, including across different species.[25] This horizontal gene transfer allows for the rapid dissemination of resistance. Key PMQR mechanisms include:

• qnr Genes: These genes encode pentapeptide repeat proteins (Qnr proteins) that protect the bacterial topoisomerases from ciprofloxacin's action, likely by binding to the enzymes and preventing the drug from stabilizing the cleavage complex.[24]
• aac(6')-Ib-cr: This gene encodes a variant of an aminoglycoside acetyltransferase enzyme that has evolved the additional ability to acetylate the piperazine ring of ciprofloxacin, thereby inactivating the drug.[25]
• Plasmid-Encoded Efflux Pumps: Plasmids can also carry genes for their own efflux pumps, such as OqxAB and QepA, which add to the cell's capacity to expel the antibiotic.[25]

While PMQR mechanisms often confer only a low level of resistance on their own, their presence can create a permissive environment that facilitates the selection of higher-level chromosomal mutations, thus accelerating the overall evolution of resistance.[24]

9.2 Evolutionary Trajectories to High-Level Resistance

Experimental evolution studies have illuminated the typical stepwise pathway by which bacteria develop high-level resistance to ciprofloxacin.[86] This process generally occurs in two stages:

• Stage 1 (Initial Resistance): Under initial or low-level drug pressure, a single mutation arises that confers a low-to-moderate level of resistance (e.g., a 4- to 16-fold increase in the MIC). This is most commonly a mutation in the QRDR of the primary target gene (gyrA in Gram-negatives) or a mutation that upregulates an efflux pump.[86]
• Stage 2 (High-Level Resistance): If the bacterium continues to be exposed to the antibiotic, it acquires additional mutations in the background of the first one. These secondary mutations may occur in the other topoisomerase target (parC or parE), in other efflux pump regulators, or in porin genes. The cumulative effect of these mutations leads to the high levels of resistance observed in clinically challenging infections.[86]

9.3 Epidemiological Trends and Surveillance (CDC Data)

The molecular evolution of resistance has translated into alarming epidemiological trends. The Centers for Disease Control and Prevention (CDC) has identified antimicrobial resistance (AR) as an urgent public health threat, responsible for over 2.8 million infections and 35,000 deaths annually in the U.S. prior to the COVID-19 pandemic.[89] The pandemic has further exacerbated the problem, with a documented increase in hospital-onset AR infections.[89]

A critical and recent example of this trend is the emergence of ciprofloxacin resistance in Neisseria meningitidis, the causative agent of meningococcal meningitis and sepsis.

• Historically, resistance in this organism was rare in the U.S. However, since 2019, the number of invasive meningococcal disease cases caused by ciprofloxacin-resistant strains has increased sharply.[92]
• This development has profound public health implications. Ciprofloxacin has long been a first-line agent for chemoprophylaxis in close contacts of meningococcal disease cases due to its efficacy as a single oral dose. The rise of resistance threatens to cause prophylaxis failures.[92]
• In response, the CDC has issued new guidance for health departments. It recommends that in local areas where ciprofloxacin resistance meets a specific threshold (e.g., ≥2 resistant cases and ≥20% of all cases being resistant over a 12-month period), prophylaxis should preferentially be given with alternative agents like ceftriaxone, rifampin, or azithromycin.[92]

This shift in national public health policy for a life-threatening disease is a direct and stark consequence of the clinical impact of ciprofloxacin resistance, demonstrating how molecular events in bacteria can necessitate major changes in established medical practice.

Section 10: Synthesis and Expert Recommendations

10.1 The Duality of Ciprofloxacin: Balancing Efficacy and Risk

Ciprofloxacin embodies the central duality of many powerful antibiotics: it is both a highly effective therapeutic tool and a medication with significant liabilities. On one hand, its broad spectrum of activity, particularly against challenging Gram-negative pathogens like P. aeruginosa, and its excellent pharmacokinetic profile have made it an indispensable agent for treating a range of serious infections, from complicated UTIs and osteomyelitis to life-threatening diseases like anthrax and plague. For decades, it has allowed for the successful treatment of conditions that would otherwise require prolonged hospitalization for intravenous therapy.

On the other hand, this utility is profoundly tempered by a dual threat: a severe safety profile and the relentless rise of bacterial resistance. The accumulation of post-marketing data has unmasked the potential for disabling and potentially irreversible toxicities affecting tendons, nerves, and the central nervous system, culminating in a prominent FDA Black Box Warning. This has fundamentally shifted the drug's risk-benefit calculus, moving it from a first-line empirical choice for many common infections to a reserved agent for situations where its benefits clearly outweigh its substantial risks. Concurrently, its own success and widespread use have fueled the selection of resistant bacteria, eroding its efficacy against the very pathogens it was once reliably used to treat. The emergence of ciprofloxacin-resistant N. meningitidis, forcing a change in national prophylaxis guidelines, is a clear signal of this growing crisis.

10.2 Recommendations for Judicious Prescribing and Antimicrobial Stewardship

In light of this complex profile, the clinical use of ciprofloxacin must be governed by principles of judicious prescribing and robust antimicrobial stewardship. The following recommendations are paramount:

1. Adhere to Regulatory Guidance: Clinicians must respect the warnings and restrictions issued by regulatory bodies like the FDA and EMA. Ciprofloxacin should be reserved for infections that are proven or strongly suspected to be caused by susceptible bacteria and should not be used for mild, self-limiting, or non-bacterial conditions. For uncomplicated infections like acute sinusitis, acute bronchitis, and uncomplicated cystitis, it should only be considered when all other appropriate and safer antibiotic options are contraindicated or have failed.[37]
2. Utilize Diagnostics to Guide Therapy: Whenever possible, treatment should be guided by culture and antimicrobial susceptibility testing (AST). Empiric use should be limited and tailored to local resistance patterns. De-escalation to a narrower-spectrum agent should occur once susceptibility results are known. This practice not only ensures optimal treatment for the individual patient but also minimizes unnecessary selective pressure.[29]
3. Prioritize Patient Counseling and Monitoring: Given the risk of severe adverse effects, thorough patient counseling is essential. Patients must be informed of the early signs and symptoms of tendinitis (pain, swelling), peripheral neuropathy (numbness, tingling, burning pain), and CNS effects (confusion, agitation) and instructed to discontinue the drug and seek immediate medical attention if they occur. They must also be counseled on critical drug and food interactions, particularly the need to separate doses from antacids, dairy, and mineral supplements to ensure adequate absorption.[37]
4. Dose Appropriately: Dosing must be carefully tailored to the patient, with particular attention to renal function. Dose adjustments for patients with renal impairment are mandatory to prevent toxicity. The pharmacodynamic principle of concentration-dependent killing suggests that preserving peak concentrations through interval extension may be a superior strategy to dose reduction in this population.[62]

10.3 Future Perspectives: Overcoming Resistance and the Role of Fluoroquinolones

The future of ciprofloxacin and the entire fluoroquinolone class is inextricably linked to the challenge of antimicrobial resistance. As resistance continues to spread, the empirical utility of these agents will further decline. Future efforts must focus on strategies to mitigate and overcome this threat. This may include the investigation of ciprofloxacin in combination with other agents, such as nanoparticles or bacteriophages, that could potentially restore its activity against resistant isolates or biofilm communities.[4]

Ultimately, the story of ciprofloxacin is a powerful and cautionary tale in modern medicine. It illustrates the typical life cycle of a successful antibiotic: a period of great promise and widespread use, followed by the inevitable emergence of resistance and the delayed recognition of rare but serious toxicities. It underscores the fact that antibiotics are a finite resource. Preserving the long-term viability of ciprofloxacin and other essential antimicrobials depends entirely on a collective commitment to stewardship, ensuring these powerful drugs are used only when necessary, at the correct dose, and for the appropriate duration.

Works cited

1. Ciprofloxacin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00537
2. www.nhs.uk, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/about-ciprofloxacin/#:~:text=About%20ciprofloxacin%20Brand%20names%3A%20Ciproxin,bacteria%20that%20causes%20an%20infection.
3. Ciprofloxacin | C17H18FN3O3 | CID 2764 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ciprofloxacin
4. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic - Frontiers, accessed July 21, 2025, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.1025633/full
5. Ciprofloxacin - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535454/
6. Ciprofloxacin | CAS 85721-33-1 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, https://www.scbt.com/p/ciprofloxacin-85721-33-1
7. Ciprofloxacin - CAS Common Chemistry, accessed July 21, 2025, https://commonchemistry.cas.org/detail?cas_rn=85721-33-1
8. CAS Number 85721-33-1 | Ciprofloxacin - Spectrum Chemical, accessed July 21, 2025, https://www.spectrumchemical.com/cas/85721-33-1
9. Ciprofloxacin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 21, 2025, https://www.rxlist.com/ciprofloxacin/generic-drug.htm
10. Ciprofloxacin Tablets (Cipro): Uses & Side Effects - Cleveland Clinic, accessed July 21, 2025, https://my.clevelandclinic.org/health/drugs/18639-ciprofloxacin-tablets
11. Ciprofloxacin (oral route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-oral-route/description/drg-20072288
12. About ciprofloxacin - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/about-ciprofloxacin/
13. Ciprofloxacin Bayer - referral | European Medicines Agency (EMA), accessed July 21, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-bayer
14. Ciprofloxacin Bayer Article 30 REFERRAL Annexes I-IV - EMA, accessed July 21, 2025, https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_en.pdf
15. CAS RN | 85721-33-1 - Thermo Fisher Scientific, accessed July 21, 2025, https://www.thermofisher.com/search/cas/85721-33-1
16. Ciprofloxacin 85721-33-1 | TCI AMERICA, accessed July 21, 2025, https://www.tcichemicals.com/US/en/p/C2510
17. Cipro, Cipro XR (ciprofloxacin) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 21, 2025, https://reference.medscape.com/drug/cipro-xr-ciprofloxacin-342530
18. How and when to take or use ciprofloxacin - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/how-and-when-to-take-or-use-ciprofloxacin/
19. Ciprofloxacin Kabi Annexes I - II - III - EMA, accessed July 21, 2025, https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_en.pdf
20. CIPROFLOXACIN (Teva), 0.3% w/v, Eye Drops - Medsafe, accessed July 21, 2025, https://www.medsafe.govt.nz/profs/datasheet/c/ciprofloxacintevadrops.pdf
21. Ciprofloxacin Ear Drops: Package Insert / Prescribing Info - Drugs.com, accessed July 21, 2025, https://www.drugs.com/pro/ciprofloxacin-ear-drops.html
22. Ciprofloxacin Completed Phase 1 Trials for Chronic Obstructive Pulmonary Disease (COPD) / Infections Treatment | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00537/clinical_trials?conditions=DBCOND0031289%2CDBCOND0024541&phase=1&purpose=treatment&status=completed
23. Mechanism of action of and resistance to quinolones - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3815421/
24. Mechanisms of Resistance to Quinolones | Clinical Infectious Diseases - Oxford Academic, accessed July 21, 2025, https://academic.oup.com/cid/article/41/Supplement_2/S120/307501
25. Mechanism of Quinolone Action and Resistance - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3985860/
26. CIPRO (ciprofloxacin hydrochloride) - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf
27. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects, accessed July 21, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics
28. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIPRO safely and effecti - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019537s095,020780s050lbl.pdf
29. CIPRO (ciprofloxacin hydrochloride - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf
30. Distribution and Antimicrobial Activity of Ciprofloxacin in Human Soft Tissues - ASM Journals, accessed July 21, 2025, https://journals.asm.org/doi/10.1128/aac.43.5.1307
31. www.nhs.uk, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/about-ciprofloxacin/#:~:text=Ciprofloxacin%20is%20a%20broad%2Dspectrum,skin%20and%20bone%20infections
32. Ciprofloxacin - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Ciprofloxacin
33. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions - ASM Journals, accessed July 21, 2025, https://journals.asm.org/doi/10.1128/aac.28.2.331
34. Resistance Pattern of Ciprofloxacin Against Different Pathogens - PMC - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3191653/
35. www.ncbi.nlm.nih.gov, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535454/#:~:text=Ciprofloxacin%20has%20FDA%20approval%20to,anthrax%2C%20plague%2C%20and%20salmonellosis.
36. Ciprofloxacin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 21, 2025, https://www.drugs.com/dosage/ciprofloxacin.html
37. Ciprofloxacin Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 21, 2025, https://www.drugs.com/ciprofloxacin.html
38. FDA Requires Stronger Black Box Warning for Antibiotics Levaquin, Cipro - Drugwatch.com, accessed July 21, 2025, https://www.drugwatch.com/news/2016/05/16/fda-black-box-warning-for-levaquin-cipro-antibiotic-risk/
39. Ciprofloxacin 500mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) | 7257, accessed July 21, 2025, https://www.medicines.org.uk/emc/product/7257/smpc
40. Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects - AIFA, accessed July 21, 2025, https://www.aifa.gov.it/documents/20142/1804926/2023.05.22_com-EMA_Antibiotici-fluorochinolonici_EN.pdf
41. Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects - GOV.UK, accessed July 21, 2025, https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
42. Fluoroquinolones: restrictions on use - BASG, accessed July 21, 2025, https://www.basg.gv.at/en/market-surveillance/official-announcements/detail/fluoroquinolones-restrictions-on-use
43. Bacterial Diseases Completed Phase 3 Trials for Ciprofloxacin (DB00537) - DrugBank, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0031058/clinical_trials/DB00537?phase=3&status=completed
44. Ciprofloxacin Completed Phase 2 Trials for Critically Ill Patients / Hospital Acquired Infections / Systemic Inflammatory Response Syndrome (SIRS) / Pneumonia / Fever Treatment - DrugBank, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00537/clinical_trials?conditions=DBCOND0031463%2CDBCOND0020923%2CDBCOND0044758%2CDBCOND0014196%2CDBCOND0053489&phase=2&purpose=treatment&status=completed
45. Upper Respiratory Tract Infection Completed Phase Trials for Ciprofloxacin (DB00537), accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0035535/clinical_trials/DB00537?phase=&status=completed
46. Bacterial Diseases Recruiting Phase 4 Trials for Ciprofloxacin (DB00537) | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0031058/clinical_trials/DB00537?phase=4&status=recruiting
47. CIPRO® (ciprofloxacin hydrochloride) TABLETS ... - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019537s082,020780s040lbl.pdf
48. Ciprofloxacin: MedlinePlus Drug Information, accessed July 21, 2025, https://medlineplus.gov/druginfo/meds/a688016.html
49. FDA adds “black box” warning label to fluoroquinolone antibiotics - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2483892/
50. Should cipro (ciprofloxacin) be used in the elderly for urinary tract infections (UTI) when it has the lowest minimum inhibitory concentration (MIC)? - Dr.Oracle, accessed July 21, 2025, https://www.droracle.ai/articles/93286/should-cipro-be-used-in-the-elderly-if-it-has-the-lowest-mic-in-a-uti
51. Safety Considerations of Fluoroquinolones in the Elderly | Request PDF - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/41823759_Safety_Considerations_of_Fluoroquinolones_in_the_Elderly
52. Ciprofloxacin Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 21, 2025, https://www.drugs.com/sfx/ciprofloxacin-side-effects.html
53. Cipro Side Effects: What They Are and How to Manage Them - Healthline, accessed July 21, 2025, https://www.healthline.com/health/drugs/cipro-side-effects
54. Side effects of ciprofloxacin - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/side-effects-of-ciprofloxacin/
55. Ciprofloxacin oral tablet side effects: How to manage them - Medical News Today, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/drugs-ciprofloxacin-tablet-side-effects
56. Ciprofloxacin (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-intravenous-route/description/drg-20072232
57. Ciprofloxacin (Systemic: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed July 21, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/ciprofloxacin-systemic
58. Ciprofloxacin: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 21, 2025, https://www.medcentral.com/drugs/monograph/7748-388016/ciprofloxacin-oral
59. Ciprofloxacin - LiverTox - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548066/
60. Ciprofloxacin dosage guide: Form, strengths, when to take, and more - Medical News Today, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/drugs-ciprofloxacin-tablet-dosage
61. Ciprofloxacin - EN (Pharmamedix), accessed July 21, 2025, https://www.pharmamedix.com/principi-attivi/en/Ciprofloxacin_EN.pdf
62. Cipro Dosage Guide - Drugs.com, accessed July 21, 2025, https://www.drugs.com/dosage/cipro.html
63. Fluoroquinolones in the elderly: safety considerations - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/12641485/
64. Pregnancy, breastfeeding and fertility while taking or using ciprofloxacin - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/pregnancy-breastfeeding-and-fertility-while-taking-or-using-ciprofloxacin/
65. Is Cipro (ciprofloxacin) contraindicated in pregnancy? - Dr.Oracle, accessed July 21, 2025, https://www.droracle.ai/articles/57303/is-ciprolex-contraindicated-in-pregancy
66. Ciprofloxacin Use During Pregnancy - Drugs.com, accessed July 21, 2025, https://www.drugs.com/pregnancy/ciprofloxacin.html
67. Cipro: Pregnancy and Breastfeeding Information - Healthline, accessed July 21, 2025, https://www.healthline.com/health/drugs/cipro-reproductive-health
68. Ciprofloxacin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501583/
69. Clinical pharmacology of ciprofloxacin in paediatric patients - JSciMed Central, accessed July 21, 2025, https://www.jscimedcentral.com/public/assets/articles/drugdesign-8-1079.pdf
70. Ciprofloxacin safety in paediatrics: a systematic review - PMC - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3155117/
71. CIPROFLOXACIN oral - MSF Medical Guidelines, accessed July 21, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/ciprofloxacin-oral-16683360.html
72. Ciprofloxacin Dosage Guide: The Most Common Cipro Doses - GoodRx, accessed July 21, 2025, https://www.goodrx.com/ciprofloxacin/dosage
73. What is the recommended dosing of Cipro (Ciprofloxacin) for a patient with a renal abscess and impaired renal function? - Dr.Oracle AI, accessed July 21, 2025, https://www.droracle.ai/articles/31575/cipro-dosing-for-renal-abscess
74. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/15946909/
75. Cipro: Pregnancy and breastfeeding information - Medical News Today, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/drugs-cipro-reproductive-health
76. The 10 Things to Avoid With Ciprofloxacin - GoodRx, accessed July 21, 2025, https://www.goodrx.com/ciprofloxacin/interactions
77. Cipro and Alcohol/Food Interactions - Drugs.com, accessed July 21, 2025, https://www.drugs.com/food-interactions/ciprofloxacin,cipro.html
78. Ciprofloxacin interactions to avoid | SingleCare, accessed July 21, 2025, https://www.singlecare.com/blog/ciprofloxacin-interactions/
79. Taking or using ciprofloxacin with other medicines and herbal supplements - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/taking-or-using-ciprofloxacin-with-other-medicines-and-herbal-supplements/
80. www.mayoclinic.org, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-oral-route/description/drg-20072288#:~:text=If%20you%20are%20taking%20aluminum,that%20you%20take%20this%20medicine.
81. Ciprofloxacin or Cipro: Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed July 21, 2025, https://www.wellrx.com/ciprofloxacin/lifestyle-interactions/
82. Common questions about ciprofloxacin - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/common-questions-about-ciprofloxacin/
83. www.nhs.uk, accessed July 21, 2025, https://www.nhs.uk/medicines/ciprofloxacin/common-questions-about-ciprofloxacin/#:~:text=Do%20not%20take%20the%20liquid,type%20of%20food%20and%20drink.
84. Mechanisms of quinolone action and resistance: where do we stand? - Microbiology Society, accessed July 21, 2025, https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000475
85. The resistance mechanisms of bacteria against ciprofloxacin and ..., accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9815622/
86. Shared and Unique Evolutionary Trajectories to Ciprofloxacin ..., accessed July 21, 2025, https://journals.asm.org/doi/10.1128/mbio.00987-21
87. Evolution of Ciprofloxacin Resistance-Encoding Genetic Elements in Salmonella | mSystems - ASM Journals, accessed July 21, 2025, https://journals.asm.org/doi/10.1128/msystems.01234-20
88. Mechanism of Quinolone Action and Resistance | Biochemistry - ACS Publications, accessed July 21, 2025, https://pubs.acs.org/doi/10.1021/bi5000564
89. Antimicrobial Resistance Facts and Stats - CDC, accessed July 21, 2025, https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html
90. 2019 Antibiotic Resistance Threats Report - CDC, accessed July 21, 2025, https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html
91. Antimicrobial Resistance Threats in the United States, 2021-2022 - CDC, accessed July 21, 2025, https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html
92. Public Health Strategies for Antibiotic-resistant Neisseria ... - CDC, accessed July 21, 2025, https://www.cdc.gov/meningococcal/php/antibiotic-resistant/index.html
93. Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - CDC, accessed July 21, 2025, https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7305a2-H.pdf